Ivacaftor and Mitapivat interaction

Ivacaftor and Mitapivat: both prescribing labels flag this combination with the strongest language, such as a contraindication, a boxed warning, or an instruction to avoid it.

Major

Do not combine without a prescriber's guidance. The label language below is the strongest FDA uses.

What the FDA labels say

From the Mitapivat (AQVESME) label · effective 2026-08-27

Major

Strong CYP3A Inhibitors and Inducers: Avoid concomitant use.

Drug interactionsby drug classView label on DailyMed
Major

Moderate CYP3A Inhibitors: Avoid concomitant use.

Drug interactionsby drug classView label on DailyMed
Major

Prevention or Management Avoid co-administration of strong CYP3A inhibitors with AQVESME [see Dosage and Administration (2.4) ] .

Drug interactionsby drug classView label on DailyMed
Major

Prevention or Management Avoid co-administration of moderate CYP3A inhibitors with AQVESME [see Dosage and Administration (2.4) ] .

Drug interactionsby drug classView label on DailyMed
Moderate

Effect of Other Drugs on AQVESME Strong CYP3A Inhibitors Clinical Impact Co-administration of AQVESME with strong CYP3A inhibitors increased mitapivat plasma concentrations [see Clinical Pharmacology (12.3) ] .

Drug interactionsby drug classView label on DailyMed

From the Ivacaftor (Kalydeco) label · effective 2026-03-23

Moderate

Concomitant Use with CYP3A Inducers Use of KALYDECO with strong CYP3A inducers, such as rifampin, substantially decreases the exposure of ivacaftor, which may reduce the therapeutic effectiveness of KALYDECO.

Warnings and precautionsby drug classView label on DailyMed
Moderate

Inducers of CYP3A Co-administration with rifampin, a strong CYP3A inducer, significantly decreased ivacaftor exposure (AUC) by approximately 9-fold.

Drug interactionsby drug classView label on DailyMed
Minor

Use with CYP3A inducers: Concomitant use with strong CYP3A inducers (e.g., rifampin, St.

Warnings and precautionsby drug classView label on DailyMed
Minor

Therefore, co-administration of KALYDECO with strong CYP3A inducers (e.g., rifampin, St.

Warnings and precautionsby drug classView label on DailyMed
Minor

Therefore, co-administration with strong CYP3A inducers, such as rifampin, rifabutin, phenobarbital, carbamazepine, phenytoin, and St.

Drug interactionsby drug classView label on DailyMed

Taking more than these two? Interactions stack. Check your whole list at once; it stays in your browser.

Open in the checker

Not medical advice. Interaction Checker quotes FDA label text and NIH fact sheets. Whether an interaction matters for you depends on doses, timing, kidney and liver function, and other conditions. Confirm with a pharmacist or prescriber.